Cystic Fibrosis Lung, Non-Tuberculous Mycobacterial Pneumonia
Conditions
Keywords
scRNASec
Brief summary
In this project the investigators aim to identify new biological markers by characterizing the response/inflammation associated with the development and progression of M. abscessus lung disease in patients suffering from cystic fibrosis with the aim of increasing current knowledge available on the development and progression of lung disease.
Detailed description
Main objective: Evaluate the correlation between early alterations in the profile of specific cell populations or expression markers or soluble immunity activation proteins, considering in particular the development and progression of M. abscessus lung disease in patients with cystic fibrosis. Secondary objectives * Identify cellular expression profiles associated with the development and progression of M. abscessus lung disease in cystic fibrosis patients and evaluate its ability to predict clinical outcome * Identify biomarkers or molecular profiles associated with the development and progression of M. abscessus lung disease in cystic fibrosis patients and evaluate its ability to predict clinical outcome * Expand pathogenetic knowledge to support disease progression pulmonary disease from M. abscessus in patients with cystic fibrosis and evaluate their ability to predict clinical outcome. * Describe the reciprocal interactions between cellular and humoral components of the response inflammatory disease during M. abscessus infection with/without M. abscessus lung disease.
Interventions
OTHERLuminex; scRNAsec
Evaluation of specific cell populations associated with development of M. abscessus lung disease; evaluation of circulating factors related to immunoresponses
Sponsors
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Ospedale San Raffaele
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patients with a certain diagnosis of cystic fibrosis and visited during normal clinical practice, in accordance with the standard operating procedures in force at the Centres. * Both sexes * Age \>18 years * Obtaining informed consent for patients (based on the procedures established by the protocol).
Exclusion criteria
* Patients unable to understand the instructions and information provided and be able to adequately accept the study methods.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| profile of specific cell populations and expression markers to determine the development and progression of M. abscessus lung disease in patients with CF | One month after enrollment visit | Evaluate the correlation between early alterations in the profile of specific cell populations or expression markers or soluble immunity activation proteins, considering in particular the development and progression of M. abscessus lung disease in patients with cystic fibrosis |
Countries
Italy
Contacts
Primary ContactNicola I Lorè, PhD
Outcome results
None listed